Methotrexate Orion

Methotrexate, the active ingredient in Methotrexate Orion, is an antimetabolite presented as an oral tablet for oral use. It treats rheumatoid arthritis, psoriasis, and certain cancers such as acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease.

GNH USA supplies Methotrexate Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate is used in autoimmune disorders and malignancies that involve rapidly dividing cells.

Rheumatoid arthritis: reduces inflammation and slows joint damage in adult patients. Psoriasis: decreases skin cell proliferation and improves plaque lesions. Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission. Non‑Hodgkin lymphoma: inhibits tumor growth in certain lymphoma subtypes. Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mouth sores or ulceration. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Severe liver toxicity or hepatitis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone marrow suppression leading to pancytopenia.

Methotrexate requires careful monitoring and specific safety measures.

Monitor liver function: perform regular hepatic enzyme tests. Monitor blood counts: check complete blood count frequently. Avoid use in pregnancy: drug is contraindicated due to teratogenicity. Avoid live vaccines: immunosuppression may increase infection risk. Adjust dose in renal impairment: reduce dosage or increase monitoring. Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Methotrexate can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Sulfonamide antibiotics: may potentiate hematologic toxicity. - Trimethoprim‑sulfamethoxazole: heightens risk of bone marrow suppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance. - Live vaccines: increased risk of infection due to immunosuppression.